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SUMMARY - Neuropa thic pain refers to pain that originates from pathology of the nervous
system. Common causes of neuropathic pain are diabetes mellitus, reactivation of herpes zoster,
nerve compression or radiculopathy, alcohol, chemotherapy or abuse of some drugs, and trigeminal
neuralgia. Specific symptoms of neuropathic pain are mechanical allodynia and cold hyperalgesia.
Drugs to treat neuropathic pain can be divided into adjuvant analgesics (antidepressants and anti-
convulsants), opioids and topical agents. The use of multiple drug therapies is common in practice.
Despite considerable increase in the number of randomized placebo-controlled trials in neuropathic
pain in the last few years, the medical treatment of neuropathic pain is still far from being satisfac-
tory, with less than half of patients achieving significant benefit with any pharmacological drug.
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Introduction
Neuropathic pain is defined as 'pain initiated or
caused by a primary lesion or dysfunction of the ner-
vous system", Neuropathic pain, in contrast to noci-
ceptive pain, is described as 'burning', 'electric', 'tin-
gling', and 'shooting' in nature. It can be continuous
or paroxysmal in presentation. Whereas nociceptive
pain is caused by the stimulation of peripheral of A-
delta and C-polymodal pain receptors by algogenic
substances (e.g., histamine bradykinin, substance P,
etc.), neuropathic pain is produced by damage to, or
pathologic changes in the peripheral or central ner-
vous systems.
Examples of pathologic changes include prolonged
peripheral or central neuronal sensitization, central
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sensitization related damage to the nervous system
inhibitory functions, and abnormal interactions be-
tween the somatic and sympathetic nervous systems.
The hallmarks of neuropathic pain are chronic allo-
dynia and hyperalgesia. Allodynia is defined as pain
resulting from a stimulus that ordinarily does not elic-
it a painful response (e.g., light touch). Hyperalgesia is
defined as an increased sensitivity to normally painful
stimuli. Primary hyperalgesia, caused by sensitization
of C-fibers, occurs immediately within the area of the
injury. Secondary hyperalgesia, caused by sensitiza-
tion of dorsal horn neurons, occurs in the undamaged
area surrounding the injury.
It can be a debilitating and difficult condition to
treat and is often resistant to simple analgesics, re-
quiring additional analgesic approaches'. It is not only
devastating for patients but also places considerable
demands on the society, including financial burdens





Neuropathic pain is generated by electrical hy-
peractivity of neurons along the pain pathways. The
sensory pathway consists of at least three neurons,
and lesions anywhere along the pathway can lead to
neuropathic pain. Changes in the expression of neu-
ronal ion channels and receptors, synaptic connectiv-
ity, and anatomy all contribute to neuropathic pain
(neural plasticity)">, Clinical investigations of pain
mechanisms are labor intensive and require special-
ized equipment; thus, they are not yet practical for
routine clinical use. Even in specialized pain research
settings, it is difficult to identify specific neuropathic
pain mechanisms. A simple focal peripheral nerve in-
jury unleashes a range of peripheral and central ner-
vous system processes that can all contribute to persis-
tent pain and abnormal sensation".
Inflammation, reparatory mechanisms of neural
tissues in response to injury, and the reaction of ad-
jacent tissues to injury lead to a state of hyperexcit-
ability in primary afferent nociceptors, a phenomenon
termed peripheral sensitization. In turn, central neu-
rons innervated by such nociceptors undergo dramatic
functional changes including a state of hyperexcit-
ability termed central sensitization. Normally these
sensitization phenomena extinguish themselves as
the tissue heals and inflammation subsides. However,
when primary afferent function is altered in an en-
duringway by injury or disease of the nervous system,
these processes persist and may be highly resistant to
treatment".
Injury or permanent loss of primary afferent fibers
(deafferentation) differentiates peripheral neuropathic
pain from other types of pain. Positive sensory phe-
nomena (spontaneous pain, allodynia, and hyperalge-
sia) that are characteristic of patients with neuropathic
pain are likely to have many underlying mechanisms,
including ectopic generation of impulses as well as
the de novo expression of neurotransmitters and their
receptors and ion channels. Direct injury to central
structures may permanently alter sensory processing,
and in some patients it causes central neuropathic pain
and dysesthesias. The mechanisms underlying central
neuropathic pain, however, are still unclear 9-11.
Increased understanding of the underlying mecha-
nisms has allowed for identification of new pharma-
cological targets and development of new neuropathic
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medications; however, so far it has not helped identify
patients that are likely to respond to individual treat-
ments.
Diagnosis ofNeuropathic Pain
Neuropathic pain syndromes typically have both
negative and positive sensory symptoms and signs!',
Nonsensory neurologic symptoms and signs depend
on the underlying cause and may independently con-
tribute to pain and disability. Although neuropathic
pain has been defined by the International Association
for the Study of Pain as pain "initiated or caused by a
primary lesion or dysfunction in the nervous system",
several investigators have recently argued that the in-
clusion of the term 'dysfunction' makes this definition
vague and unacceptably broads The proposed solution
is to define neuropathic pain as pain caused by a lesion
of the peripheral or central nervous system (or both)
manifesting with sensory symptoms and signs. Dem-
onstrating a lesion of the nervous system compatible
with particular symptoms and signs provides strong
support for considering the pain to be neuropathic.
However, when no lesion can be demonstrated, the
limits of current diagnostic technology do not always
allow for the possibility of neuropathic pain to be
excluded. The diagnosis of neuropathic pain is based
on medical history, review of systems, physical and
neurologic examination, and appropriate laboratory
studies including blood and serologic tests, magnetic
resonance imaging, and electrophysiologic studies13.
In some instances, nerve or skin biopsy is necessary to
visualize nerve fibers directly.
Our ability to translate pain complaints and senso-
ry findings into specific pathophysiologic mechanisms
that have treatment implications is in its infancy7,14,15.
Treatment
Regardless of the cause, neuropathic pain affects
mul tiple aspects ofthe patient's life. The management of
neuropathic pain involves a multidisciplinary approach.
Therapy for neuropathic pain includes the use of both
non-interventional (pharmacological, psychological,
and physical therapy) and interventional therapies.
Without due concern of the diagnosis, rehabilita-
tion, and psychosocial issues, treatment has a limited
chance of success. For peripheral nerve lesions, mobi-
lization is needed to prevent trophic changes, disuse
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atrophy, and joint ankylosis. Surgery may be needed
to alleviate compression. Psychological factors should
be constantly considered from the start of treatment.
Anxiety and depression should be treated appropri-
ately. When dysfunction is entrenched, patients may
benefit from comprehensive approach provided by a
pain clinic.
Pharmacotherapy
The best clinical approach to applied pharmacol-
ogy currently incorporates empiric observation and
identification of the possible mechanisms of neuro-
pathic lesion and then uses the best available phar-
macological information to match these potential
disease mechanisms with putative drug mechanisms.
Although monotherapy is the ideal approach, rational
polypharmacy is often pragmatically used.
Several classes of drugs are moderately effective,
but complete or near-complete relief is unlikely. An-
tidepressants and anticonvulsants are most commonly
used. Evidence of efficacy is strong for several antide-
pressants and anticonvulsants.
Opioid analgesics can provide some relief but are
less effective than for nociceptive pain; adverse ef-
fects may prevent adequate analgesia. Topical drugs
and a lidocaine-containing patch may be effective for
peripheral syndromes. Sympathetic blockade is usu-
ally ineffective except for some patients with complex
regional pain syndrome":".
Antidepressants
Tricyclic antidepressants (TCAs) are often regard-
ed as first-line drugs for neuropathic pain. A recent
systematic review of the literature, in which num-
bers needed to treat (NNTs) of treatments for differ-
ent neuropathic pain syndromes were calculated, has
found TCAs to be the most efficacious drugs for neu-
ropathic pain (NNT 3.1; 95% confidence interval (CI)
2.7-3.7)19.20 This is based on the results from no less
than 15 placebo-controlled designed trials, which uni-
formly demonstrated efficacy ofamitriptyline, nortrip-
tyline, desipramine, chlomipramine, imipramine and
maprotiline, at a daily dose range of 30-200 mg, for
post-herpetic neuropathy (PHN) and diabetic pain-
ful neuropathy (DPN)'1 The main drawback of these
trials is the small number of recruited patients in each
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of them. Yet, taken together, they provide a strong
level of evidence for efficacy. Notably, two small trials
found TCAs to be superior to placebo for central post-
stroke pain and post-mastectomy neuropathic pain,
whereas several others failed to demonstrate efficacy
for spinal-cord injury pain, human immunodeficien-
cy virus (HIV) neuropathy and phantom limb pain.
Unfortunately, "l'C'As are associated with numerous
adverse events and are not tolerated by many patients.
When used, slow titration is required, especially in
the elderly".
Two trials demonstrated efficacy of the selective
serotonin reuptake inhibitors (SSRls) citalopram and
paroxetine (both at 40 mg/day) in DPN23 In another
trial, fluoxetine was equal to placebo".
The selective serotonin and norepinephrine reup-
take inhibitors (SNRls) venlafaxine and duloxetine
are newer antidepressants that have shown efficacy for
DPN at daily doses of 150- 225 mg and 60-120 mg,
respectively. The NNTs of4.6 (CI 2.9-10.6) for venla-
faxine and 5.2 (CI 3.7-8.5) for duloxetine are superior
to that of SSRls but inferior to TCAs'- In two large
randomized controlled trials (RCTs), duloxetine also
significantly improved sleep and quality of life. Its
most common adverse events are nausea, somnolence,
dizziness and constipation, which all tend to decrease
over time. The drug should not be used concomitant-
ly with monoamine oxidase (MAO) inhibitors or in
patients with impaired liver function. One notable
advantage of the antidepressants (with the exception
of venlafaxine) is that they can be administered once
daily25.26 .
Side effectsof tricyclic antidepressants
The most common side effects of TCAs are dry
mouth, constipation, sweating, dizziness, disturbed
vision, drowsiness, palpitation, orthostatic hypoten-
sion, sedation and urinary hesitation. More selective
TCAs such as nortriptyline are better tolerated than
the non-selective ones, with less anticholinergic ef-
fects and sedation. A suspected association between
TCA treatment and sudden cardiac death has raised
concern; a recent epidemiological study found a slight
increase in sudden cardiac death with TCA doses
greater than 100 mg/day. Therefore, caution is recom-




The SNRIs (duloxetine, venlafaxine) are safer to
use than TCAs and are a better option in patients
with cardiac disease. The relative risk of withdrawal
due to side effects is weak and there is no need for
drug level monitoring. The most frequently observed
adverse events with duloxetine are nausea, vomiting,
constipation, somnolence, dry mouth, hyperhidrosis,
loss of appetite and weakness. Although immediate
release of venlafaxine is associated with adverse cen-
tral nervous system (CNS) and somatic symptoms
such as agitation, diarrhea, increased liver enzymes,
hypertension and hyponatremia, the extended release
formulation seems to be by far more tolerable, the
main side effects being gastrointestinal disturbances.
.dnticomndsants
In addition to antidepressants, selected anticon-
vulsants are often regarded as first line drugs for
neuropathic pain. Randomized clinical trials (RCTs)
have shown the efficacy of gabapentin, pregabalin,
lamotrigine, carbamazepine and, to a lesser extent,
some other anticonvulsants. Yet, with the exception
of trigeminal neuralgia, the challenge of 50% pain
relief in more than half of these patients is rarely
metl6,27.
The most extensively studied drug in this class is
pregabalin, which has shown efficacy for (PHN) and
(DPN) in a large number of multicenter RCTs. The
effective daily dose of 300-600 mg can reduce pain
and improve sleep, functioning and quality of life.
Pregabalin can be rapidly titrated. Unfortunately, the
drug has not been studied in other types ofneuropathic
pain. The most commonly reported adverse events oc-
curring during all controlled clinical trials were dizzi-
ness, somnolence, dry mouth and edema. Weight gain
can also be a problem in some patients-".
There is also strong evidence for the efficacy of
gabapentin (900-3600 mg/day) for PHN and DPN.
Although less broadly studied in other syndromes,
gabapentin has shown efficacy in HIV-associated
painful neuropathy, pain in Guillain-Barre's syn-
drome, phantom limb pain, cancer related neuropath-
ic pain and complex regional pain syndrome type III
RCTs have shown efficacy of lamotrigine for DPN,
central post stroke pain, trigeminal neuralgia and
mixed neuropathies, and of carbamazepine and
oxcarbazepine for trigeminal neuralgia, DPN and
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mixed neuropathies. The need for a relatively slow
titration and the adverse effect profile of these drugs
make them a second line of antiepileptic treatment
for these conditions, except for trigeminal neuralgia.
Equivocal or negative (active therapy not superior
to placebo) results were reported with lamotrigine
for spinal cord injury pain, HIV-related neuropathy
and mixed neuropathies, with topiramate for PDN,
and with valproate for DPN and spinal cord injury
pain-".
Side effects of anticonvulsants
Carbamazepine entails frequent adverse events,
which include sedation, dizziness, and gait abnor-
malities. Liver enzymes, blood cells, platelets and so-
dium levels should be monitored for at least one year
because of the possible risk of hepatitis, anaplastic ef-
fects or hyponatremia. The induction of microsomal
enzyme systems may influence the metabolism of
several drugs. In contrast to carbamazepine, oxcarba-
zepine does not entail enzymatic induction and there
is little risk of crossed cutaneous allergy. In the first
months of treatment, sodium levels should be moni-
tored because oxcarbazepine, like carbamazepine,
induces hyponatremia, particularly in the elderly (6%
in a cohort of 54 patients). As regards other side ef-
fects, although better tolerance has been claimed with
oxcarbazepine as compared with carbamazepine, this
notion lacks coxnsistent evidence from class I trials.
In a recent trial in diabetic painful polyneuropathy,
27.5% of the oxcarbazepine group versus 8% of the
placebo group discontinued treatment due to central
or gastrointestinal side effects.
The most common side effects of gabapentin and
pregabalin include dizziness, somnolence, peripheral
edema, and dry mouth, with a similar frequency for
both drugs. Whilst gabapentin is widely accepted as
highly tolerable even at high dosages (>2400 mg), the
reports on pregabalin change remarkably with the
daily dose: with 150 to 300 mg there is almost no
difference from placebo, whilst the withdrawal rate
reaches 20% with 600 mg.
Lamotrigine is generally well tolerated. Side ef-
fects include dizziness, nausea, headache and fatigue.
However, it may induce potentially severe allergic skin
reactions. Lamotrigine should not be used in combi-
nation with valproate.
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Opioids
Eight RCTs tested the efficacy of oral opioids for
PDN, PHN, phantom pain and neuropathic pain of
diverse etiologies. Four drugs were tested: morphine,
oxycodone, methadone and levorphanol. All trials re-
ported that opioids were efficacious in reducing spon-
taneous neuropathic pain by demonstrating either
superiority to placebo or a dose-dependent analgesic
response. Six of the eight studies were recently pooled
to a meta-analysis, which found a mean pain inten-
sity to be by 14 points lower in opioid-treated patients
than in those treated with placebo (95% CI -18 to -10;
P<0.001)!6 .17 The overall NNT of opioids for neuro-
pathic pain is 2.5 (CI 2.0-3.2). Secondary outcome
parameters such as physical and mental health, sleep
and disability were measured in parts of these trials
and yielded inconsistent results. Tramadol, which is
not a typical opioid, yet has a weak affinity for opioid
receptors, has been effective for DPN and PHN with
NNT of 3.9 (CI 2.7-6.7)S Common adverse events
of opioids include nausea, constipation, dizziness and
drowsiness.
Side effects
The most common side effects ofopioids are consti-
pation, sedation, nausea, dizziness and vomiting. The
risk of cognitive impairment has been reported to be
negligible, although morphine may impair attention
at very high dosages. Tramadol has been reported to
induce dizziness, dry mouth, nausea, constipation and
somnolence with significantly more dropouts com-
pared with placebo. There is an increased risk of sei-
zures in patients with a history ofepilepsy or receiving
drugs which may reduce the seizure threshold. Sero-
tonergic syndrome (various combinations of myoclo-
nus, rigidity, hyperreflexia, shivering, confusion, agi-
tation, restlessness, coma, autonomic instability, fever,
nausea, diarrhea, flushing, and rarely, rhabdomyolysis
and death) may occur if tramadol is used as an add-on
treatment to other serotonergic medications (particu-
larly selective serotonin reuptake inhibitors, SSRIs).
Topical Agents
Topical capsaicin cream has shown efficacy for
DPN and PHN but its use is associated with burn-
ing, particularly during the first weeks of treatment.
This can pose major problems, especially in patients
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primarily experiencing allodynia. Some studies report
on patients that had seen an average of eight different
physicians prior to referral to the pain clinic3o,31.
The application of topical lidocaine patches was
found effective for PHN in three short-term RCTs
and can also be used in patients with other focal pe-
ripheral neuropathieso".
Drug Combinations
While combinations ofdrugs with different mech-
anisms of action are commonly used in clinical prac-
tice, only one trial tested the efficacy and safety of a
combination of two drugs, and found that gabapentin
plus morphine was more efficacious and safer than ei-
ther drug alone". This trial implies the possibility that
polypharmacotherapy could enhance analgesia with
fewer side effects.
Noninvasive Therapies
One ofthe simplest forms of noninvasive treatment
for pain is transcutaneous electrical nerve stimulation
(TENS). It has been used since the 1960s, following
the development of the gate control theory of pain
transmission by Melzack and Walls The technique
is based on the interaction between small and large
afferent fibers, which converge on the dorsal horn
neurons before projecting to higher centers, and is a
useful adjunctive treatment that is virtually free from
adverse effects".
Invasive Therapies
The range of neurosurgical techniques used to
treat neuropathic pain has increased over time and
includes nerve modulation (e.g., dorsal column stim-
ulation) and ablation". Numerous ablative surgical
techniques to destroy nerves have been described, in-
cluding nerve avulsion or section, dorsal rhizotomy,
spinal dorsal root entry zone lesions, spinothalamic
tractotomies, thalamotomies, cingulotomy, frontal
lobotomy, and even destruction of the primary sen-
sory cortex. However, these treatments are generally
not recommended as they cause more damage to the
nervous system, which can intensify the neuropathic
pain. Furthermore, none of these surgical techniques
has been found to be uniformly successful in treat-
ing patients with neuropathic pain. Indeed, there are
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many examples in the literature of patients who have
undergone surgical therapies to treat pain (e.g., due
to nerve injury, trigeminal neuralgia, amputation, or
post-herpetic neuralgia), only to find that surgery has
exacerbated their original pain.
An invasive treatment regimen that is supported
by some clinical evidence, and a fairly convincing ra-
tionale, is spinal cord dorsal column stimulation. As
with TENS, this technique attempts to modulate
rostral nociceptive transmission in the spinal cord by
stimulation of the large diameter nerve fibers. Success
depends on patient selection, and it is generally accept-
ed that patients also suffering some ischemic pain are
particularly suited for this method of treatment". The
major advantage of this technique is that nerves are
not deliberately damaged. Similarly, clinical evidence
supports the use of microvascular decompression in
providing relatively good long-term outcome for pa-
tients with trigeminal neuralgia". Temporary nerve
blocks achieved by injection of local anesthetic (e.g.,
lidocaine) are still sometimes used, although their ef-
ficacy is controversial and few placebo-controlled tri -
als of this therapy have been performed'.
The available data clearly indicate that approaches
to the clinical management of neuropathic pain vary
according to whether the patient is being treated by
a pain specialist or by a non-specialist. While non-
specialists tend to treat individual symptoms, pain
specialists are more likely to select a drug therapy that
is targeted towards the mechanisms that are presumed
to be causing pain in an individual patient or the anti-
neuralgic mechanisms of various drugs". The available
data clearly indicate that patients treated in special-
ized pain clinics are more likely to receive therapies
with proven efficacy for the treatment of neuropathic
pain than those treated in non-specialist clinics":".
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Sazetak
NEUROPATSKA BOL
V BasicKes. L Zavoreo, M. Ivankovii, M. Bitunjac, V Govori i V Demarin
Neuropatska bol nastaje kao posljedica disfunkcije perifernog ili sredrsnjeg iiveanog sustava. NajcdCi uzroci neuro-
patske boli su dijabetes rnelitus, reaktivacija infekcije herpes zoster, kornpresija iivaca ili radikulopatija, pretjerana kon-
zurnacija alkohola, kernoterapija ili zlouporaba lijekova te neuralgija trigerninusa. Specrficni sirnptorni neuropatske boli
su mehanicka alodinija i hladna hiperalgezija. U lijecenju neuropatske boli rabi se nekoliko skupina lijekova. U prvu sku-
pinu spadaju adjuvantni lijekovi, a to su antidepresivi i antiepileptici, opioidi i lokalna sredstva. U praksi se najceSce rabi
kornbinacija dviju ili vise vrsta lijekova. Unatoc brojnirn randorniziranirn, placeborn kontroliranirn studijarna na podrucju
neuropatske boli rnedikarnentno hjecenje neuropatske boli jos uvijek nije zadovoljavajuce, te se zadovoljavajuca analgezija
postiie u sarno 50% bolesnika s neuropatskorn boli.
Kljucne rijeci: Neuralgija - terapiJaliJekovima; Bol-liJdenje; Mjerenje boli;Analgetici - terapiJskaprimjena; TerapiJaliJeko-
vima - kombinirana
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